
AMOMED Pharma Offers Drugs for Severe COVID-19 Cases



AMOMED Pharma develops medicinal products for patients suffering from septic shock at the intensive care units. Septic shock is a life-threatening complication in COVID-19 patients.

Most COVID-19 admissions to the intensive care unit are due to severe lung disorders requiring invasive mechanical ventilation; many with acute respiratory distress syndrome. Acute respiratory distress syndrome (ARDS) is associated with a higher incidence of pulmonary arterial hypertension.

Experimental studies showed that pulmonary arteries were not constricted with arginine-vasopressin in contrast to conventional vasopressors.

Vasopressin is a natural hormone produced in the pituitary gland that controls the narrowing (constriction) and widening (dilation) of blood vessels. The body has a severe deficit of this substance in septic shock. Vasopressin, together with norepinephrine, can help to stabilize critically low blood pressure in septic shock.

[AMOMED Pharma](#) is the only pharmaceutical company in the European Union with an approval for the use of arginine-vasopressin for catecholamine refractory hypotension in septic shock to raise mean arterial blood pressure. The use of arginine vasopressin in the treatment of COVID-19 in septic shock has now been included in national and international guidelines¹.

Clinicians and other healthcare professionals can register at <https://www.amomed.com/register/?lang=en> to learn more about the applicable patient profile for arginine-vasopressin. If you have any questions about the effects of vasopressin, please contact us at medinfo@amomed.com.

The current COVID-19 outbreak has become an enormous challenge for hospitals and medical staff. The AMOMED team would like to thank everyone in the healthcare sector for this enormous effort.

Published on : Thu, 23 Apr 2020